Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

transvestites treatment 187

12th World AIDS Conference

-Keyword

Abstract -

SKeyword

Abstract
ention of HIV-STD with sex workers in Bahia, Brazil 44174
educes the incidence of treatment-emergent respiratory tract infe 31205
with two nucleosides in treatment-naive HIV-1-seropositive perso 12145
nd lamivudine (3TC) in patients with >500 CD4 c 12311
hly or poorly effective in or AZT - Experienced HI 22382
Genotypic resistance in patients/Genotypic resis 32313
urse for HIV-1 infected patients/The Five-to-No 41194
ns in HIV-1 strains from patients (Luxembourg 19 42199
th zidovudine (ZDV) in HIV-1 patients with 50-2 60358
uring protease inhibitor treatment or by mutants in the viral protea 11132
rophylaxis and antiviral /HIV patients' survival in Mexico 12111
saquinavir (SQV) in the of AIDS patients, in Brazil/Safet 12114
ith zidovudine (ZDV) /Reduction of maternal-infant tr 12155
nd neonatal zidovudine in reduction of perinatal HIV-1 tr 12156
ollowing antiretroviral during primary HIV infection/Ra 12185
hibitor (S-1153) for the of HIV infection: A phase I study 12214
us ZDV + 3TC + IDV in naive HIV-infected patients (ST 12223
us ZDV + 3TC + IDV in naive HIV-infected patients (ST 12225
nation regimens for the of antiretroviral naive, HIV-infec 287*/12235
apeutic strategies (no vs double therapy (ZDV/d4T + 3 12238
C 0.375 mg TID for the of HIV-1 infection in a Thai stud 12240
rences in antiretroviral.Data from the Eurosida study g 437*/12272
inavir in patients failing including a protease inhibitor (P 12285
Viral load levels during with Viracept combination treat 12300
navir protease inhibitor in a BID regimen as salvage the 12303
A study of the effects of in women + HIV-infected with co 12305
iretroviral combination: Data on 4230 patients in the Ital 12312
e, clinical sequalae and /Lipid abnormalities associated 12319
rotease inhibitors in the of HIV-infected children/Effecti 12320
ghly active antiretroviral (HAART) on neutrophil and mo 12322
nd hepatic tolerance of with protease inhibitors in HIV a 12326
hly active antiretroviral /Changes in CD4+ cell count an 12331
hly active antiretroviral (HAART) in France/Clinical ma 12345
iarrhea (NFVID)/The (TX) of nelfinavir (NFV) induced 12383
adefovir dipivoxil in the of HIV infection/Safety of adefo 12386
profile of Viracept in the of HIV patients: The French co 12393
Burkina Faso/Care and: Increased access at low cost in 75*/12405
ed during follow-up and of HIV-infected patients in a Tur 12431
mbination antiretroviral in antiretroviral-naive patients w 12444
Development of the HIV satisfaction survey (HTSS) to i 12445
IP clients/State of HIV information in Japan - From the 12448
groups in anti-retroviral effectiveness/The importance 12454
users admitted to drug in six US cities/Age-specific tre 13224
s among patients on TB /Factors contributing to reporte 13275
ccess to STD care and at Government General Hospita 13482
STDs prevention, care, and support/To build a bridge b 13492
e US substance abuse system and efforts to improve a 13586
ention/Nigerian youth's seeking behavior for STD: Targ 14115
ons for prevention and /Co-occurring HIV and metham 14157
rrelates at an urban day center/Quality of life correlates 14350
ession and response to /Infection with different HIV-1 su 21105
uring HIV infection and /No evidence for proliferation in 21121
nfection/Diagnosis and for community-acquired pneum 22116
New perspective in the of multi drug resistant tuberculo 22125
ase of tuberculosis (TB) in HIV-1 infected Ugandan adult 454*/22140
al amikacin (LA) for the of non-tuberculous mycobacteri 22170
nd ethambutol in the of M. avium complex (MAC) bac 22176
sus ciprofloxacin for the of chancroid/Randomized, dou 22189
Ramadan's fast on the of genital discharge with Erythro 22209
and clinical response to of oral thrush/Correlation of ser 22219
nt oral fumagillin for the of Enterocytozoon bieneusi infe 22232
dose fomivirsen for the of CMV retinitis/Safety profile of 22245
ractice of CMV retinitis with cidofovir in experienced pat 22256
f ganciclovir/Induction of CMV: A comparison between 22267
hly active antirretroviral (HAART)/Nonprogression of C 22271
hly active antiretroviral (HAART) in patients with AIDS- 617*/22275
acid (Panretinr) gel as of cutaneous AIDS-related Kap 618*/22277
combined antiretroviral /Regression of AIDS-related Ka 22288
e genital tract following of cervical intraepithelial neopla 22310
nt of infection rates and outcomes/Human papilloma vir 22315
estoration disease after of immunodeficient HIV-infecte 340*/22323
uccessful antiretroviral of glomerulonephritis in a HIV p 22330
on of new guidelines for of HIV infection/Access to com 22333
oviral regimens for the of HIV infection/OZCOMBO 1: 22348
ole of viral resistance in failure/Long-term effectiveness 22353

I therapy and following with HIV-1 protease inhibitors/ 22357
profile of antiretroviral of ritonavir in combination with z 22409
HIV positive patients in for tuberculosis/Ambulatory nur 60*/22467
and holistic therapy for and care for PWAs in the Asia P 22487
mproved antiretroviral does not affect sexual decision- 23130

bitors/Interferon-a-2B
ethadone maintenance
ns who injecting drug in
s in Seattle, USA/Drug
nset drug users outside
delivery with zidovudine
horts/Combining ZVD
rapartum and neonatal
gh viral load under AZT
IV testing and perinatal
y: The effect of antiviral
on drug users in a drug
nd bisexual men/AIDS
ailand/STD testing and
vention strategies in the
g a residential drug-free
uation of changing HIV
ty level/The cost of HIV
apeutic regimes for the
otype and antiretroviral
ghly active antiretroviral
mmune responses after
at baseline and during
ation of an algorithm for
ns and the response to
iarrhea/SP-303: A new
of interferon (IFN) a-2a
UR) in HIV+ males and
ow optimal ganciclovir
mphoma. Results of the
act of protease inhibitor
encephalopathy (PML)
ution with antiretroviral
n diabetic patients after
CV) as an option for the
I trial/Thalidomide as a
n a province-wide drug
n: Medical and surgical
ted patients: Results of
patients as predictor of
combination therapy in
ce computer system in
ilure after 12 months of
ghly active antiretroviral
on of protease inhibitor
atment decisions/HIV
nitoring/Self reported
vice delivery models for
nt reasons/Obstacles in
Emerging issues in HIV
V(+) IDUs as barriers to
hadone and other drug
nd families/Monitoring
users admitted to drug
women's access to STD
erian adolescents/STD
c rise/The effect of HIV
d diseases (STDs) and
nge, drug use, and drug
avior/Recruiting out-ofhe changing meaning of
ct of drug maintenance
mmunication skills in the
e substance abusers in
rs, on seeking modern
The impact of anti-viral
al fitting to antiretroviral
The impact of HIV/AIDS
es in combination drug
d AIDS prevention and
RE Act/Emerging care/
edictors of response to
during 6 months as first
intermittent out-patient

c transplantation for the
nts/Interleukin-2 (IL-2)
mmune responses after
3TC after combination
ng/Providing HIV/AIDS
National programme of

for chronic hepatitis in the AIDS 23146
and incident HIV infection amon 23179
and prisoners in Tijuana, Baja C 23218
and HIV risk reduction among in 23223
settings/HIV-risk and preventio 23232
/Decreased perinatal HIV-1 tran 23272
and elective cesarean section r 23291
in preventing maternal infant HI 23292
/Mother-to-child transmission of 23308
and intervention strategies/Te 23317
on the shedding of cell-free and 23392
program/Lesser virologic respo 23398
advances and perceived need t 23403
acceptance and factors associa 23509
of HIV+ substance users/Interv 23541
facility in New York City, 1993-1 23560
patterns in Ontario, Canada/An 24129
and care at the community level 24130
of HIV/AIDS/Incremental drug c 24134
/Cytotoxic T lymphocytes and vi 31138
(HAART)/Specific T-cell respo 111*/31142
with an inactivated gpl20-deple 31151
/Expression of CD28 and CD38 116*/31170
of respiratory conditions in HIV- 31208
among AIDS patients treated at 31215
for AIDS-associated diarrhea/S 32106
in chronic hepatitis C (HCV) in H 32116
with doxazosin/Increased urina 32126
of CMV infection in neutropenic 32146
in 36 cases/AIDS-associated ly 32159
on body composition and preval 32177
with cidofovir/Progressive multi 562*/32193
including protease inhibitors/Pr 32194
for CMV retinitis (CMVR) with g 32236
of cytomegalovirus retinitis (CM 32244
of HIV-related oral ulcers: A dou 32247
program/The relationship betw 32254
of 400 cases/Mucocutaneous i 32266
with foscarnet/Acyclovir-resista 32269
failure in high acting antiretrovir 233*/32282
experienced HIV/AIDS patients, 32295
experienced HIV-infected patie 32297
in ART-naive HIV+ patients/HA 32319
/Strategies to optimise adheren 388*/32322: A clinical survey/Reasons for d 32353
compliance (adherence) and dr 32363
adherence and drug/alcohol us 32379
adherence to combination antir 32383
adherence: Patient reasons/Ob 32400
adherence/Prisons and public 501*/32408
/Physician perceptions of HIV(+ 32412
programs in New York/Co-locat 32421
adherence in pediatric HIV: Ide 32438
in three US metropolitan areas/ 33197
in Nepal/Integrated reproductiv 83*/33237
and prevention among Nigerian 33244
on population infection levels is 33257
seeking behaviors among rural 33342
in Seattle area drug injectors/T 33387
injection drug users (IDUs) into 33398
effectiveness/Methadone and 33406
on HIV-related risk behaviours 33413
decision making process/Partn 33520
/Preventing HIV/AIDS by mobili 33604; A study conducted on 1997 in t 34129
combinations on the social care 34241
campaign/Integral fitting to antir 34301
advances on community based 34310
/UK ASO programme to enable 34315
/Cochrane Collaborative Revie 252*/34356
issues and trends in resource all 34380
of HIV-1 infected children with t 41191
course for HIV-1 infected treatm 41194
with sub-cutaneous interleukin- 344*/41230

of AIDS/Xenogeneic porcine th 41232
reduces soluble CD30 (sCD30) 41235
with a gp 120-depleted, inactiva 41237
with indinavir/Low frequency of 42197
education to an ethnically divers 42229
workshops for people directly at 42230